A preliminary agreement has been reached with the TRND program at the NIH to collaborate with Dr Klassen’s team on translational development of the novel human retinal progenitor cell approach to treating RP.
The annual ARVO meeting was held in Seattle for the first time. This year’s meeting included a number of special sessions devoted to the use of stem cells for treatment of retinal diseases, highlighting the high level of interest in this topic. Our project was presented in poster form. In addition, there was a pre-meeting focused on the challenges facing startup companies in the ophthalmic field which was quite informative.
We are currently preparing for the initiation of formal IND-enabling preclinical studies. These are the final studies needed in order to get permission from the FDA to begin clinical trials.